Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation

The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors.

We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities.

Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively.

AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.

Future oncology (London, England). 2018 Jan 10 [Epub ahead of print]

Veronica Prati, Fiorella Ruatta, Caterina Aversa, Angela Gernone, Danilo Galizia, Alessandro Bonzano, Sofia Torino, Imperia Nuzzolese, Laura Marandino, Massimo Aglietta, Cinzia Ortega

Medical Oncology I, Fondazione Del Piemonte Per l'Oncologia, IRCCS Candiolo, Turin, Italy., Medical Oncology, Policlinico di Bari, Bari, Italy., Medical Oncology II, Fondazione Del Piemonte Per l'Oncologia, IRCCS Candiolo, Turin, Italy., Cardiology Unit, Fondazione Del Piemonte Per l'Oncologia, IRCCS Candiolo, Turin, Italy.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe